When initial therapy proves insufficient, treatment escalation includes: Biologic DMARDs targeting specific inflammatory pathways (TNF inhibitors, IL-6 inhibitors, T-cell costimulation blockers, B-cell depleting agents) Targeted synthetic DMARDs such as JAK inhibitors (tofacitinib, baricitinib, upadacitinib), which carry FDA boxed warnings for serious cardiovascular events, malignancy, and thrombosis [24] [25] Combination DMARD therapy Short-term glucocorticoids for symptom control during treatment initiation Before starting biologic or targeted synthetic DMARDs, screening for tuberculosis and hepatitis B is recommended, along with appropriate vaccinations according to ACR guidelines
Because Rybelsus requires specific administration conditions (empty stomach, 30-minute wait), attempting to take a missed dose later in the day is not recommended and is likely to result in reduced absorption and effectiveness
McCauley JF, Dean RC
Genetic rearrangements among the RET tyrosine kinase domain and heterologous genes are the root of RETs carcinogenic potential in PTC
How it works: In theory, TB-500 regulates actin, a protein that helps healing cells migrate to injury sites
